导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.83% | 1646/4775 |
| 近一周 | -2.21% | 3503/5468 |
| 近一月 | -0.57% | 3054/5401 |
| 近一季 | -7.21% | 3097/5193 |
| 近半年 | 3.97% | 1235/4905 |
| 近一年 | 12.82% | 1522/4330 |
| 近两年 | 58.93% | 1232/2947 |
| 近三年 | 16.39% | 1566/2226 |
| 成立以来 | 113.01% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.37% 2767/4961 |
11.33% 2346/5312 |
- - |
- - |
| 2025 | 26.82% 1604/4813 |
-2.19% 2857/3635 |
-1.79% 3269/4076 |
30.82% 1156/4524 |
0.92% 1656/4813 |
| 2024 | -3.43% 2217/3463 |
-3.35% 1493/2808 |
-11.08% 2502/3014 |
19.12% 886/3129 |
-5.67% 2579/3463 |
| 2023 | -17.47% 1738/2656 |
2.70% 1313/2280 |
-12.24% 2178/2385 |
-3.99% 1036/2515 |
-4.63% 1117/2655 |
| 2022 | -20.29% 956/2207 |
-21.29% 1611/1919 |
14.23% 205/2016 |
-13.55% 917/2113 |
2.55% 901/2208 |
| 2021 | -4.04% 938/1822 |
-6.78% 1039/1255 |
12.79% 309/1330 |
-14.29% 1365/1466 |
6.48% 216/1822 |
| 2020 | 74.01% 59/1250 |
-2.23% 256/1028 |
28.29% 112/1067 |
15.84% 192/1164 |
19.76% 69/1184 |
| 2019 | 60.04% 53/1092 |
33.89% 124/739 |
5.21% 16/788 |
5.17% 160/850 |
8.03% 363/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 中金MSCI质量A VS. 长安沪深300非周期A(740101) |